Every 10-Q that Bausch Health Companies Inc (BHC) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BHC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BHC filings page.
Bausch Health Companies Inc. delivered stronger quarterly results but a much weaker first half in 2026. For the three months ended June 30, 2026, total revenues were $2,852 million, up from $2,530 million in 2025, and net income attributable to Bausch Health rose to $258 million from $148 million. Basic earnings per share for the quarter increased to $0.69 from $0.40.
For the six‑month period, however, the company reported a net loss attributable to Bausch Health of $1,165 million versus net income of $90 million a year earlier, driven largely by a $1,426 million goodwill impairment in the Salix reporting unit following failed Phase 3 clinical trials. This contributed to a shift from positive equity to a total shareholders’ deficit of $1,771 million and total (deficit) equity of $(802) million as of June 30, 2026, with total assets of $24,794 million and total liabilities of $25,596 million.
Operating cash flow remained solid, with net cash provided by operating activities of $900 million for the first half of 2026, up from $500 million in 2025, and cash and cash equivalents increased to $1,825 million. Long‑term debt and other borrowings had principal amounts totaling $20,239 million, generating first‑half interest expense of $798 million. The company continues to pursue the separation of its majority‑owned Bausch + Lomb business, while Xifaxan® intangible assets carried a value of $808 million with an estimated remaining useful life of 18 months amid ongoing generics litigation.
Bausch Health Companies Inc. reports first-quarter 2026 results showing a sharp swing to loss driven by a major goodwill write-down. Revenue reached $2,524 million, up from $2,259 million a year earlier, but operating performance was overshadowed by non-cash charges.
The company recorded a $1,426 million goodwill impairment in its Salix reporting unit after Phase 3 trial failures, leading to a net loss of $1,431 million versus a $86 million loss in 2025. Shareholders’ equity moved from positive $377 million at year-end 2025 to a deficit of $1,082 million, while long-term debt remained high at $20,212 million principal.
Bausch Health Companies Inc. reported stronger Q3 2025 results. Revenue reached $2.681 billion versus $2.510 billion a year ago, and operating income rose to $619 million from $318 million. Net income attributable to Bausch Health was $179 million, compared with a loss of $85 million, translating to diluted EPS of $0.48.
For the first nine months, revenue was $7.470 billion and net income attributable to Bausch Health was $269 million with diluted EPS of $0.72. Operating cash flow was $905 million. Cash and cash equivalents were $1.308 billion, and total assets were $26.824 billion.
Debt and equity shifted due to refinancing: current portion of long-term debt decreased to $579 million from $2.674 billion, while non‑current long-term debt increased to $20.463 billion. Total equity improved to $356 million from a deficit of $(322) million at year‑end. The company acquired DURECT for $84 million, expensing $81 million as acquired IPR&D tied to Larsucosterol. Bausch + Lomb remained approximately 88% owned, and the company continues to evaluate completing the B+L separation.
Common shares outstanding were 370,516,926 as of October 24, 2025.